Docetaxel is under clinical development by Starpharma and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Docetaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Docetaxel (nano-formulation) is under development for the treatment of solid cancers, pancreatic cancer, gastric cancer, including non-small cell lung cancer, prostate, esophageal cancer, bile duct cancer (cholangiocarcinoma). It is administered through intravenous route. The drug candidate is developed based on dendrimer nanotechnology. It was also under development for the treatment of small cell lung cancer, gastro-oesophageal, breast, cervical, renal and brain cancer.
Starpharma is a biotechnology company, which researches, develops and manufactures dendrimer products for pharmaceutical, life sciences and other applications. Dendrimers are synthetic nanoscale polymers with pharmaceutical and medical uses. The company’s development programs include its DEP drug delivery, which is built around dendrimers and VivaGel portfolio. Its flagship product candidate, VivaGel, is a gel-based formulation for the treatment and prevention of bacterial vaginosis (BV) and it is also used as a vaginal microbicide to prevent sexually transmitted infections including HIV and genital herpes. It has license arrangements with several partners including Okamoto Industries and AstraZeneca among others. The company has research facilities in Melbourne, Australia. Starpharma is headquartered in Abbotsford, Victoria, Australia
For a complete picture of Docetaxel’s drug-specific PTSR and LoA scores, buy the report here.